BioSpace News Archive

Encoded Therapeutics today announced the upcoming presentation of initial data from the ENVISION prospective natural history study of children with SCN1A+ Dravet syndrome, a rare developmental and epileptic encephalopathy, at the American Epilepsy Society 2021 Annual Meeting, taking place in Chicago from December 3-7, 2021.

Promore Pharma releases it’s Interim Report January - September 2021.

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), today announced financial results for the quarter ended September 30, 2021 (the “second quarter of Fiscal 2022”).

Exscientia (Nasdaq: EXAI) today announced they will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT).

Nykode Therapeutics announced that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases.

Seegene Inc., a leading biotechnology firm specializing in molecular diagnostics has announced financial results for the third quarter ended September 30, 2021.

Researchers at Yale University analyzing specialized MRI exams found significant changes in the microstructure of the brain’s white matter in adolescents and young adults with autism spectrum disorder compared to a control group, according to research being presented next week at the annual meeting of the Radiological Society of North America.

Revive Therapeutics Ltd., a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for Bucillamine for the prevention of ischemia–reperfusion injury during liver transplantation.

Notable Labs, Inc., a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, announced the appointment of Chris Whitmore as Chief Financial Officer.

Amryt today announces that the US Food and Drug Administration (“FDA”) has extended the review period for the New Drug Application (“NDA”) for Oleogel-S10.